CUE VS CDXC Stock Comparison
Performance
CUE10/100
10/100
CUE returned -33.33% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
CDXC10/100
10/100
CDXC returned -23.46% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
Analyst Price Targets
CUE75/100
75/100
1 analysts offer 12-month price targets for CUE. Together, they have an average target of 7, the most optimistic target put CUE at 7 within 12-months and the most pessimistic has CUE at 7.
CDXC88/100
88/100
2 analysts offer 12-month price targets for CDXC. Together, they have an average target of 0, the most optimistic target put CDXC at 0 within 12-months and the most pessimistic has CDXC at 0.
Sentiment
CUE74/100
74/100
CUE had a bullish sentiment score of 74.32% across Twitter and StockTwits over the last 12 months. It had an average of 2.59 posts, 1.65 comments, and 3.88 likes per day.
CDXC73/100
73/100
CDXC had a bullish sentiment score of 72.97% across Twitter and StockTwits over the last 12 months. It had an average of 2.80 posts, 1.24 comments, and 2.68 likes per day.
Technicals
CUE64/100
64/100
CUE receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.
CDXC10/100
10/100
CDXC receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.
Earnings
CUE10/100
10/100
CUE has missed earnings 6 times in the last 20 quarters.
CDXC10/100
10/100
CDXC has missed earnings 6 times in the last 20 quarters.
Profit
CUE10/100
10/100
Out of the last 20 quarters, CUE has had 0 profitable quarters and has increased their profits year over year on 0 of them.
CDXC10/100
10/100
Out of the last 20 quarters, CDXC has had 0 profitable quarters and has increased their profits year over year on 0 of them.
Volatility
CUE40/100
40/100
CUE has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.
CDXC46/100
46/100
CDXC has had a lower than average amount of volatility over the last 12 months giving it a score of 45 of 100.
All score calculations are broken down here to help you make more informed investing decisions
Cue Biopharma, Inc. Summary
Nasdaq / CUE
Healthcare
Biotechnology
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
ChromaDex Corporation Summary
Nasdaq / CDXC
Healthcare
Biotechnology
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare CUE to other companies in the same or a similar industry.